admin

Small biotech companies on Monday can start applying for matching grants from Montgomery County through a new program.

Read More

Recently I had the chance to hold a replica of the upper part of a human airway—the windpipe plus the first two bronchi. It had been made from collagen, the biological cement that holds our bodies together. It was slippery and hollow, with the consistency of undercooked pasta.

Read More

AstraZeneca’s MedImmune and 4D Molecular Therapeutics forged a collaboration to develop a gene therapy for chronic lung disease.

Read More

Montgomery County companies may soon apply online for the County’s new Small Business Innovation Research (SBIR) and Small Business Technology Transfer (STTR) Matching Grant Program. Applications will be accepted beginning at 10 a.m. on Monday, July 16.

Read More

MaxCyte announced that it has received Investigational New Drug (IND) clearance from the US Food and Drug Administration (FDA) to begin a clinical study in the United States with its first wholly-owned chimeric antigen receptor (CAR) therapeutic candidate, MCY-M11.

Read More

Altimmune, Inc. (Nasdaq:ALT), a clinical-stage immunotherapeutics company focused on infectious disease, today announced it has appointed Mitchel Sayare, Ph.D., as Executive Chairman of the Board, effective immediately.

Read More

A Baltimore biotechnology company has raised $4 million, to help bring its therapeutic treatment targeting rare genetic diseases closer to market.

Read More

Johns Hopkins spinout Clear Guide Medical received a $2 million grant from the National Institutes of Health to apply its imaging tools to pediatrics.

Read More

WellDoc®, a leading digital health company revolutionizing chronic disease management to help transform lives through the use of its digital therapeutics, today announced results from an innovative economic analysis that demonstrated the potential for significant healthcare cost savings with the use of BlueStar®. BlueStar is powered by WellDoc and is a 510K-cleared digital therapeutic designed to coach adults with type 2 diabetes.

Read More

True Bearing Diagnostics Inc. is working to commercialize an early-detection test for coronary artery disease, a possible game-changer for the health care industry.

Read More

The Worldwide Genomics Market report is an expert analysis report explore the market by Size, Share and Forecasts Till 2025. The Global Genomics Market size was estimated at USD 12.02 billion in 2016. It is anticipated to progress at a CAGR of 9.7% over the forecast period. Widening base of genomic data pool from genomic research activities is enabling physicians, biologists, and patients to further investigate genetic predisposition to certain diseases.

Read More

The chairman of Johns Hopkins University’s Berman Institute of Bioethics has made a $15 million gift to establish a new endowment and support studying bioethicists.

Read More

Thursday, July 19, 20184:30 – 7:00 PM EST

Spend an inspiring 10 minute ‘ideastorming’ session with the Anchor Ventures PowerTen, the most influential innovation leaders in the greater Baltimore area – build on an idea for your company, bring your ideas for a program topic, a product, a system improvement or a better way to grow our ecosystem. Complete the RSVP link with your idea and we’ll match you to our PowerTen. Then mingle with more than 150 local entrepreneurs at our networking happy hour.

Read More

The Society of Physician Entrepreneurs and the MBA Collaborative Alumni Angel Group, in conjunction with NIH, cordially invite you to join us for our next meeting:

Summer Healthcare/Life Science Pitch Event

July 24th 2018 5 PM-8 PM

This program will be focused on start-up and emerging biotech, pharmaceutical, Health IT, and healthcare companies. Referrals are coming from NIH officials and consultants as well as SoPE/CAAG members and affiliates.

Call for Start-Ups; Please submit your Executive Summary and non-proprietary Slide deck to jhausfeld@sopenet.org for consideration to pitch at this upcoming event.

Read More

Maryland companies raised $247 million in venture capital funding in the second quarter, the sixth consecutive quarter the state has raised at least $100 million.

Read More

Want to hear more about cybersecurity and technology in Montgomery County? Check out the personal stories from our most innovative business leaders and entrepreneurs in the fields of IT, BioHealth, life sciences, and more.

Read More

Venture funding for Greater Washington companies fell nearly 50 percent in the second quarter from a year ago, but the region’s take for the first half of the year remains above last year.

Read More

The National Institute of Standards and Technology issued a request for information seeking ideas for improving the public’s return on investment from federally supported R&D. Here’s my submission.

Read More

The Bill & Melinda Gates Foundation has held a coming-out party for its nonprofit biotech startup. Equipped with plans to build a 120-person team and spend $100 million a year, the Gates Medical Research Institute (MRI) will turn drug industry expertise and processes on intractable diseases that kill millions of people annually in low- and middle-income countries.

Read More

The region has only seen one real initial public offering since the beginning of 2017.

Read More

The prospect of Amazon entering the pharma industry with the acquisition of PillPack will be a troubling development for pharma executives around the globe.

Read More

This recently re-surfaced brainteaser has been making the rounds on the internet again. Apparently, reported Sharesplosion, if you can find the “C’ that’s hidden somewhere among the rows and rows of “Os” in under seven seconds, you’re a genius (they claim that 99% of adults can’t achieve this feat).

Read More

Alexandria Real Estate Equities, Inc. (NYSE: ARE), an urban office REIT uniquely focused on collaborative life science and technology campuses in AAA innovation cluster locations, today announced it has acquired 219 East 42nd Street for $203 million on a fee simple basis, through a membership interest in the purchasing entity 219/235 East LLC. As part of the transaction, 219/235 East LLC leased back 219 East 42nd Street on a triple net basis to Pfizer Inc., which announced earlier this year plans to relocate its global office headquarters to Manhattan’s Hudson Yards neighborhood in 2022. Ideally located in the heart of Manhattan’s East Side Medical Corridor with critical adjacency to New York City’s renowned academic and medical institutions, the acquisition of this approximately 350,000 RSF, 10-story office building represents significant and immediate net operating income growth with a strong yield from an investment-grade tenant.

Read More

The Chronicle‘s executive-compensation package includes the latest data on more than 1,400 chief executives at more than 600 private colleges from 2008-15 and nearly 250 public universities and systems from 2010-17. Hover over bars to show total compensation as well as pay components including base, bonus, and other.

Read More

This seed round will send the startup into the next phase of its journey toward clinical trials.

Read More

In this new episode of BioTalk, Rip Ballou, MD, VP & Head, GSK Global Vaccines US R&D Center and BHI President & CEO Rich Bendis discuss GSK’s move to the BioHealth Capital Region, their Vaccines Portfolio/Future, and the importance of succeeding in the industry today.

W. Ripley Ballou, MD is Vice President and Head, GSK Global Vaccines U.S. R&D Center in Rockville, MD – Just outside of Washington, DC. Prior to this he was VP and Head, Clinical Research and Translational Science, Vaccine Discovery and Development at GSK Vaccines in Rixensart, Belgium. Previously he served as Deputy Director for Vaccines, Infectious Diseases Development, Global Health at the Bill & Melinda Gates Foundation. Dr. Ballou is an expert in vaccine development and has worked in this field for more than 30 years. Trained in Internal Medicine and Infectious Diseases, he began his work on vaccines at the Walter Reed Army Institute of Research where he led the team that with GlaxoSmithKline co-developed RTS,S, the world’s most advanced malaria vaccine. Dr. Ballou has numerous publications in the field of vaccine development and infectious diseases.

Listen now on iTunes , Google Play , and TuneIn. 

Read More

Every entrepreneur has a “founder’s story” that serves to build the unique framework for why they are just the right person to solve a specific problem. For Aaron Chang, CEO of Renalert, that story began at Johns Hopkins University in the Masters of Bioengineering Innovation and Design program.

Read More

Attending the Farm Progress Show at Boone, Iowa, this year? Add the Iowa AgriTech Accelerator to your list of exhibitors to visit.

Read More

WellDoc®, a leading digital health company, today announces hypertension and weight management solutions integrated within its digital therapeutic app for type 2 diabetes, BlueStar®. Later this year, WellDoc will launch its stand-alone product for individuals living with hypertension (high blood pressure) and stand-alone products are also in development for multiple chronic diseases.

Read More

When Viela Bio spun out of MedImmune in March, it started with six assets — three in clinical trials and three in preclinical development — putting it ahead of most startups and many spin-offs. “Other spin-offs often are developing assets that have been shelved for various reasons or that have been deprioritized,” Bing Yao, Ph.D., CEO, notes. “But for Viela Bio, this is a continuation of the programs, not a handoff.”

Read More

TEDCO, Maryland’s economic engine for technology companies, announced its recent investments through the Maryland Innovation Initiative (MII). With the latest round of funding, MII’s funding count for FY18 includes 38 technology assessment grants and seven start-up investments for a total of $5.56 million. True to its technology agnostic funding history, this year the startups ranged from medical devices to aeronautics and the sports industry.

Read More

CosmosID a bioinformatics provider and NGS service laboratory announced that the company’s cloud-based bioinformatics platform for microbiome analysis has received the highest score in the strain-level microbial profiling category of the Mosaic Community Challenge and for strain-level microbial identification in the precisionFDA Pathogen Detection Challenge.

Read More

gel-e Inc., announces the 510(k) clearance of gel-e FLEX by the U.S. Food and Drug Administration (FDA) for the over-the-counter (OTC) use of its first flowable hemostat.

This new clearance expands the Company’s label that now includes the use of gels and bandages in the local management of bleeding, such as lacerations and minor bleeding. These products are specifically designed to create rapid hemostasis through easy-to-use applications for professional healthcare providers, parents, coaches, adult caregivers and even patients themselves. gel-e FLEX also complements the Company’s already FDA cleared vascular closure device, Vascular gel-e®, as it can be worn home by patients to manage any residual bleeding from an out-patient diagnostic or interventional procedure, see http://www.gel-e.co/products.html.

Read More

With federal funding, Gemstone Biotherapeutics is eying development of the next generation of its wound-healing technology.

The Federal Hill startup is developing treatments that enable skin regeneration without scars.

Read More

The quest for innovation is a major driving force in pharma. From the discovery of therapeutic biologicals in the 1920s, such as Salvarsan and insulin, to the blockbuster drugs birthed in the 1990s, such as Lipitor and Humira, pharma has always been on a quest for novel, groundbreaking drug development.

Read More

Teva Pharmaceutical Industries Ltd., the troubled Israeli manufacturer of generic drugs, will be moving its US headquarters from Pennsylvania to New Jersey, lured by 10-year, $40 million tax incentive plan.

Read More